A team of University of Tokyo researchers said Thursday it will begin later this month the nation’s first clinical study on a vaccine for the Ebola virus.
The new vaccine developed by Yoshihiro Kawaoka, a professor at the university’s Institute of Medical Science, and others is believed to have fewer side effects compared to those produced abroad, according to the institute. It will be developed using an artificially produced detoxified virus.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.